N/A N=162 Brief COVID-19 Intervention for People With Serious Mental Illness and Co-Morbid Medical Conditions
Mental Illness · Chronic Disease
Primary: Number of Participants Who Received COVID-19 Vaccine — 56; 50 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=40 Ovarian Function With ENG Implant and UPA Use
Contraception
Primary: Number of Participants With Ovulation With Implant-alone — 7; 0 Participants
Phase 1 N=42 Inhibition of Sterile Inflammation by Digoxin
Inflammatory Response
Primary: Lower Levels of Spontaneous Reactive Oxygen Species (ROS) Production
N/A N=252 Impact on Mental, Physical, And Cognitive Functioning of a Critical Care sTay During the COVID-19 Pandemic
Covid19 · Critical Care · Postintensive Care Syndrome
Primary: World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) — 5; 13.5 units on a scale
Phase 2 N=30 Mirabegron and Physiological Function in Cold Environments
Resting Energy Expenditure · Thermogenesis · Brown Adipose Tissue
Primary: Cumulative Resting Energy Expenditure — 456.4; 494.7; 481.3; 492.8 kcal
N/A N=104,438 The STOP-HPV Trial 1: Communication Intervention
Immunization · Vaccination
Primary: Change in the Rate of Missed Vaccination Opportunities Among All Clinicians — 37063; 40764; 14932; 18343 Eligible visits (due for vaccine)
Phase 2 N=38 A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis
Colitis, Ulcerative
Primary: Percentage of Participants in Clinical Response at Week 12 — 53.8; 50.0 Percentage of participants
Phase 2 N=6 VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa
Status Epilepticus, Electrographic · Coma
Primary: Primary Pharmacologic Outcome - Absorption — 6; 0 Participants
Phase 2 N=512 A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
Infections, Respiratory · Virus Diseases · Infection Viral
Primary: Number of Participants With Solicited Local Reactions at the Injection Site (Pain, Tenderness, Erythema/Redness, Induration/Swelling) Recorded up to 7 Days After Each…
N/A N=148 Healthy, Immunized Communities Study
Vaccine Hesitancy · Communicable Diseases in Children
Primary: Percentage of Participants With Intent to Vaccinate Adolescent Child (Tdap, MCV, HPV) — 74.3; 83.3; 97.9; 93.0 percentage of participants
Phase 1 N=72 Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules
Hypertension · Heart Failure
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Prazosin — 85.77; 88.37; 92.39; 192.3 nanogram*hour per…
Phase 4 N=641 Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men
Gonorrhea · Chlamydia · Syphilis
Primary: Number of Quarterly Visits In Which an STI Was Detected — 61; 82; 36; 39 No. quarterly visits with STI event
N/A N=673 ANCHORS Study: UH2 Project
HIV-1-infection
Primary: Quantity of Alcohol Consumption — 11.38; 7.81; 4.78 drinks
Phase 3 N=50 Management of Post-Tonsillectomy Pain in Pediatric Patients
Pain, Postoperative · Tonsillar Hypertrophy · Tonsillitis
Primary: Number of Participants With FLACC Pain Scores ≥7 From POD 1 Through POD 3 — 1; 1 participants
Phase 3 N=50 Sedation Using Intranasal Dexmedetomidine in Upper Gastrointestinal Endoscopy
Gastrointestinal Disease
Primary: Consumption of Rescue Patient Controlled Propofol — 42.4; 28.6 mg